TRANSACTION STATUS
🟢 DEAL COMPLETED: Covetrus merged with MWI Animal Health (February 18, 2026) - Press Release
INDUSTRY
Animal Health Distribution & Technology Platforms
OVERVIEW
Covetrus, Inc. is a global animal-health technology and services company offering practice management software, pharmacy solutions, and supply chain services to veterinary practices, operating across companion, equine, and large-animal markets (en.wikipedia.org). MWI Animal Health is a leading distributor of animal health products and services, serving veterinarians and producers with supply chain solutions and technology tools (mwiah.com). On February 18, 2026, Covetrus and MWI Animal Health entered into a definitive merger agreement to create a combined company delivering a comprehensive animal health platform, aligned across distribution, technology, and services (covetrus.com).
PRODUCTS/SERVICES
Covetrus, Inc.
- Practice management software (e.g., VetSuite, Pulse™)
- Online pharmacy and prescription management solutions
- Medications, supplies, and equipment distribution
- Diagnostic tools, client engagement platforms, workflow and productivity solutions (covetrus.com)
MWI Animal Health
- Animal health products distribution (companion, equine, production animals)
- Technology-enabled solutions for prescription management (e.g., Furscription), equipment health monitoring, digital DEA logs (Repleni‑Trac Vault) (mwiah.com)
CUSTOMERS
Covetrus, Inc.
- Independent veterinary practices (companion, equine, large animal)
- Corporate veterinary groups and clinics
- Suppliers and manufacturers in animal health (covetrus.com)
MWI Animal Health
- Veterinarians (companion and production animal clinics)
- Livestock producers and dealers
- Manufacturers engaged in the animal health supply chain (mwiah.com)
M&A MATRIX TABLE
| Same Customers | Different Customers | |
|---|---|---|
| Same Products/Services | Cell 1 - N/A - Overlapping offerings are complementary rather than identical | Cell 2 - N/A - Different core services; overlap limited |
| Complementary/Adjacent Products/Services | Cell 3 - Combination of Covetrus's tech-enabled software platforms with MWI’s distribution and supply chain capabilities creates strong adjacency | Cell 4 - The merged entity will serve additional segments (e.g., producers) with both tech and distribution solutions |
| Different Products/Services | Cell 5 - N/A - Not pure diversification; strategic complementarity | Cell 6 - N/A - Both operate within the animal health ecosystem, not distinct markets |
Cell 3 – The transaction brings together Covetrus’s technology, pharmacy, and practice management platforms with MWI’s distribution networks and supply chain solutions, creating a strongly complementary fit. (covetrus.com)
Cell 4 – The merger expands the customer base into adjacent market segments (e.g., producers, dealers) beyond Covetrus’s core veterinary practice-focused clients, while combining diverse offerings. (covetrus.com)
SYNERGIES
- Improved logistics and cost efficiencies by integrating MWI’s distribution capabilities with Covetrus’s technology platforms (covetrus.com)
- Enhanced service offerings across the animal health ecosystem, enabling a unified platform for veterinarians, producers, dealers, and manufacturers (covetrus.com)
- Opportunity to create savings and invest in innovation through combined operations and scale (covetrus.com)
RISKS
- Integration complexity across supply chain, technology, and operations could lead to disruption in service delivery (covetrus.com)
- Cultural misalignment between distribution-focused and technology-focused organizations may hamper execution
- Regulatory approvals and stakeholder alignment (manufacturers, customers) may delay the merger or introduce operational challenges (covetrus.com)
STRATEGIC THOUGHTS
- Unifying tech and distribution strengthens Covetrus’s position as a comprehensive platform leader in animal health, offering end-to-end solutions
- The merger supports growth in production animal markets alongside companion animal segments, broadening revenue sources
- The combined scale provides leverage in negotiations with manufacturers and enhances competitiveness
FINANCIAL ANALYSIS
- Deal values MWI at enterprise value of $3.5 billion (covetrus.com)
- Cencora receives $1.25 billion in cash and $800 million in preferred equity while retaining a 34.3% stake in the combined entity (covetrus.com)
- Financial guidance for fiscal 2026 remain reaffirmed by Cencora (covetrus.com)